ZYBERNO
Stock Report
Updated Aug 23, 2026

Basel Medical Group Ltd (BMGL)

Healthcare • NASDAQ

$5.30

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
5.0/100
POOR BUSINESS
Basel Medical Group Ltd (BMGL) scores 5/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.93x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Basel Medical Group Ltd (BMGL) stock report — Zyberno Score 5/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:5.30
Market Cap:$7.29M

Valuation Multiples (3)

P/B Ratio:1.70x
P/S Ratio:0.82x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$8.89M
Ev Ebitda Ratio:9.57x

Price Action & Momentum (1)

% of 52-Week High:20.1%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:10.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.31x
Quick Ratio:1.26x
Cash Ratio:0.30x

Leverage Analysis (3)

Debt To Equity Ttm:0.93x
Debt-to-Equity Ratio:0.93x
Debt To Ebitda:4.30x

Coverage Ratios (2)

Interest Coverage Ratio:0.00x
Times Interest Earned:0.00

Capital Structure (4)

Working Capital:2,463,078.00
Cash And Cash Equivalents:2,393,636.00
Long Term Debt:$2.32M
Net Debt:$1.60M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$8.90M
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00$0.00

Bottom Line Performance (3)

-$8.36M
Income Before Tax:$0.00
Ebitda Ttm:928,633.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$328.17K
Interest Expense:160,349.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:10.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$14.69M
Current Assets:$10.45M
Ppe Net:305,572.00
Goodwill:8,076,130.38
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:10,410,996.00
Current Liabilities:7,989,000.00
Long Term Debt:$2.32M
Short Term Debt:$1.67M

Equity & Capital (3)

Equity:$4.28M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:7,460,701.00
Inventory:384,513.00
Accounts Payable:5,169,262.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$3.18M-$3.62M

Investment Activities (1)

Investing Cash Flow:-$8.57M

Financing Activities (3)

Financing Cash Flow:$12.97M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$6.08

Revenue & Cash Per Share (2)

Sales Per Share Ttm:6.47
Operating Cash Flow Per Share:-$2.31

Book Value & Capital (2)

Book Value Per Share:$3.11
Cash Per Share:1.74

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.61x
Working Capital Turnover Ttm:3.61x

Receivables Management (2)

Receivables Turnover Ttm:1.19x
Days Sales Outstanding Ttm:305.97

Inventory Management (2)

Inventory Turnover Ttm:23.15x
Days Inventory Outstanding Ttm:15.77

Payables & Cash Cycle (2)

Days Payable Outstanding:212.00
Cash Conversion Cycle:109.74
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BMGL
Company Name:Basel Medical Group Ltd
Sector:Healthcare
Industry:Services-Offices & Clinics of Doctors of Medicine
Exchange:NASDAQ
Country:Singapore

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.38M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-23 00:53:28 UTC
Data Timestamp:2026-08-21T14:13:41.714407
Scroll to Top